Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
| ▸ | ERCC1 | P07992 | 14/20 | 0.64 |
| ▸ | ERCC4 | Q92889 | 14/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28268449 | 0.86 | TRPV1 (0.52) | TRPV1ERCC1ERCC4 | |
| SCHEMBL107165 | 0.85 | ERCC1 (0.73) | TRPV1ERCC1ERCC4 | |
| SCHEMBL23417762 | 0.85 | TRPV1 (0.51) | TRPV1ERCC1ERCC4 | |
| SCHEMBL107237 | 0.84 | ERCC1 (0.81) | TRPV1ERCC1ERCC4 | |
| SCHEMBL17205984 | 0.83 | MAPT (0.71) | TRPV1ERCC1ERCC4 | |
| SCHEMBL17205705 | 0.82 | CYP1A2 (0.71) | TRPV1 | |
| SCHEMBL29213197 | 0.82 | ERCC1 (0.67) | TRPV1ERCC1ERCC4 | |
| SCHEMBL29213173 | 0.82 | ERCC1 (0.64) | TRPV1ERCC1ERCC4 | |
| SCHEMBL8269527 | 0.81 | KDM4E (0.69) | TRPV1ERCC1ERCC4 | |
| SCHEMBL15580009 | 0.81 | TRPV1 (0.67) | TRPV1ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008097692-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PROTEOTECH INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | TRPV1 4497/4885ERCC1 3598/4885ERCC4 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.